[1] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
[2] Itskovitz-Eldor J, Schuldiner M, Karsenti D, et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med. 2000;6(2):88-95.
[3] 李晴,刘靖,徐秀琴.人类多能干细胞源心肌细胞的研究进展与应用前景[J].中国细胞生物学学报,2013,35(3): 251-261.
[4] Honda M, Kiyokawa J, Tabo M, et al. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J Pharmacol Sci. 2011;117(3):149-159.
[5] Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2012;126(11 Suppl 1):S29-37.
[6] Tanaka A, Yuasa S, Mearini G, et al. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2014;3(6):e001263.
[7] Dambrot C, Braam SR, Tertoolen LG, et al. Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes. J Cell Mol Med. 2014;18(8):1509-1518.
[8] Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008;118(5): 507-517.
[9] Burridge PW, Thompson S, Millrod MA, et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One. 2011 8;6(4):e18293.
[10] Zwi-Dantsis L, Mizrahi I, Arbel G, et al. Scalable production of cardiomyocytes derived from c-Myc free induced pluripotent stem cells. Tissue Eng Part A. 2011;17(7-8):1027-1037.
[11] Fujiwara M, Yan P, Otsuji TG, et al. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One. 2011;6(2):e16734.
[12] Cao N, Liu Z, Chen Z, et al. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res. 2012;22(1):219-236.
[13] Ye L, Zhang S, Greder L, et al. Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One. 2013;8(1): e53764.
[14] Lee YK, Ng KM, Lai WH, et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes.Stem Cell Rev. 2011;7(4):976-986.
[15] Shinozawa T, Furukawa H, Sato E, et al. A novel purification method of murine embryonic stem cell- and human-induced pluripotent stem cell-derived cardiomyocytes by simple manual dissociation. J Biomol Screen. 2012;17(5):683-691.
[16] Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1): 101-113.
[17] Shinozawa T, Imahashi K, Sawada H, et al. Determination of appropriate stage of human-induced pluripotent stem cell-derived cardiomyocytes for drug screening and pharmacological evaluation in vitro. J Biomol Screen. 2012;17(9):1192-1203.
[18] Uosaki H, Fukushima H, Takeuchi A, et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One. 2011;6(8): e23657.
[19] Correia C, Serra M, Espinha N, et al. Combining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes. Stem Cell Rev. 2014;10(6):786-801.
[20] Ohno Y, Yuasa S, Egashira T, et al. Distinct iPS Cells Show Different Cardiac Differentiation Efficiency. Stem Cells Int. 2013;2013:659739.
[21] Fujita J, Fukuda K. Future prospects for regenerated heart using induced pluripotent stem cells. J Pharmacol Sci. 2014;125(1):1-5.
[22] Földes G, Matsa E, Kriston-Vizi J, et al. Aberrant α-adrenergic hypertrophic response in cardiomyocytes from human induced pluripotent cells. Stem Cell Reports. 2014;3(5):905-914.
[23] Zhang GQ, Wei H, Lu J, et al. Identification and characterization of calcium sparks in cardiomyocytes derived from human induced pluripotent stem cells. PLoS One. 2013;8(2):e55266.
[24] Iglesias-García O, Baumgartner S, Macrí-Pellizzeri L, et al. Neuregulin-1β induces mature ventricular cardiac differentiation from induced pluripotent stem cells contributing to cardiac tissue repair. Stem Cells Dev. 2015;24(4):484-496.
[25] Yang X, Rodriguez M, Pabon L, et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296-304.
[26] Kuzmenkin A, Liang H, Xu G, et al. Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J. 2009;23(12):4168-4180.
[27] Kim JJ, Yang L, Lin B, et al. Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells. J Mol Cell Cardiol. 2015;81: 81-93.
[28] Germanguz I, Sedan O, Zeevi-Levin N, et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J Cell Mol Med. 2011;15(1):38-51.
[29] Kawamura T, Miyagawa S, Fukushima S, et al. N-glycans: phenotypic homology and structural differences between myocardial cells and induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2014;9(10):e111064.
[30] Kaichi S, Hasegawa K, Takaya T, et al. Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res. 2010;88(2):314-323.
[31] Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225-229.
[32] Tan KS, Tamura K, Lai MI, et al. Molecular pathways governing development of vascular endothelial cells from ES/iPS cells. Stem Cell Rev. 2013;9(5):586-598.
[33] Sivarapatna A, Ghaedi M, Le AV, et al. Arterial specification of endothelial cells derived from human induced pluripotent stem cells in a biomimetic flow bioreactor. Biomaterials. 2015;53:621-633.
[34] Yoo CH, Na HJ, Lee DS, et al. Endothelial progenitor cells from human dental pulp-derived iPS cells as a therapeutic target for ischemic vascular diseases. Biomaterials. 2013;34(33):8149-8160.
[35] Samuel R, Daheron L, Liao S, et al. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2013;110(31):12774-12779.
[36] Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009;27(3): 559-567.
[37] Homma K, Sone M, Taura D, et al. Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells. Atherosclerosis. 2010;212(1):42-47.
[38] White MP, Rufaihah AJ, Liu L, et al. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells. 2013;31(1):92-103.
[39] Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008;118(5):498-506.
[40] Du C, Narayanan K, Leong MF, et al. Induced pluripotent stem cell-derived hepatocytes and endothelial cells in multi-component hydrogel fibers for liver tissue engineering. Biomaterials. 2014;35(23): 6006-6014.
[41] Joo HJ, Kim H, Park SW, et al. Angiopoietin-1 promotes endothelial differentiation from embryonic stem cells and induced pluripotent stem cells. Blood. 2011;118(8):2094-2104.
[42] Lee JB, Werbowetski-Ogilvie TE, Lee JH, et al. Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cells. Blood. 2013;122(7):1162-1173.
[43] Di Bernardini E, Campagnolo P, Margariti A, et al. Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor β2 (TGF-β2) pathways. J Biol Chem. 2014;289(6):3383-3393.
[44] Adams WJ, Zhang Y, Cloutier J, et al. Functional vascular endothelium derived from human induced pluripotent stem cells. Stem Cell Reports. 2013; 1(2):105-113.
[45] Margariti A, Winkler B, Karamariti E, et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A. 2012;109(34):13793-13798.
[46] Xu Y, Liu L, Zhang L, et al. Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells. PLoS One. 2012;7(4): e34321.
[47] Suzuki H, Shibata R, Kito T, et al. Comparative angiogenic activities of induced pluripotent stem cells derived from young and old mice. PLoS One. 2012; 7(6): e39562.
[48] Belair DG, Whisler JA, Valdez J, et al. Human vascular tissue models formed from human induced pluripotent stem cell derived endothelial cells. Stem Cell Rev. 2015;11(3):511-525.
[49] Zhou Y, Yang F, Chen T, et al. An updated view on the differentiation of stem cells into endothelial cells. Sci China Life Sci. 2014;57(8):763-773.
[50] Gu M, Nguyen PK, Lee AS, et al. Microfluidic single-cell analysis shows that porcine induced pluripotent stem cell-derived endothelial cells improve myocardial function by paracrine activation. Circ Res. 2012;111(7):882-893.
[51] Mauritz C, Martens A, Rojas SV, et al. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J. 2011;32(21):2634-2641.
[52] Suzuki H, Shibata R, Kito T, et al. Therapeutic angiogenesis by transplantation of induced pluripotent stem cell-derived Flk-1 positive cells. BMC Cell Biol. 2010;11:72.
[53] Prasain N, Lee MR, Vemula S, et al. Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells. Nat Biotechnol. 2014;32(11):1151-1157.
[54] Morita R, Suzuki M, Kasahara H, et al. ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells. Proc Natl Acad Sci U S A. 2015;112(1):160-165.
[55] Kim KL, Song SH, Choi KS, et al. Cooperation of endothelial and smooth muscle cells derived from human induced pluripotent stem cells enhances neovascularization in dermal wounds. Tissue Eng Part A. 2013;19(21-22):2478-2485.
[56] Templin C, Zweigerdt R, Schwanke K, et al. Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation. 2012;126(4):430-439.
[57] Citro L, Naidu S, Hassan F, et al. Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction. PLoS One. 2014; 9(12):e116281.
[58] Masumoto H, Ikuno T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014;4:6716.
[59] Wang Y, Huang W, Liang J, et al. Suicide gene-mediated sequencing ablation revealed the potential therapeutic mechanism of induced pluripotent stem cell-derived cardiovascular cell patch post-myocardial infarction. Antioxid Redox Signal. 2014;21(16):2177-2191.
[60] Carpenter L, Carr C, Yang CT, et al. Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev. 2012;21(6):977-986.
[61] Miki K, Uenaka H, Saito A, et al. Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. Stem Cells Transl Med. 2012;1(5):430-437.
[62] Matsa E, Dixon JE, Medway C, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J. 2014;35(16):1078-1087.
[63] Mehta A, Sequiera GL, Ramachandra CJ, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res. 2014;102(3):497-506.
[64] Fatima A, Kaifeng S, Dittmann S, et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS One. 2013;8(12): e83005.
[65] Hick A, Wattenhofer-Donzé M, Chintawar S, et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia. Dis Model Mech. 2013 May;6(3):608-621.
[66] Caspi O, Huber I, Gepstein A, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557-568.
[67] Drawnel FM, Boccardo S, Prummer M, et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9(3):810-821.
[68] Lin B, Li Y, Han L, et al. Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. Dis Model Mech. 2015; 8(5):457-466.
[69] Sharma A, Marceau C, Hamaguchi I, et al. Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform. Circ Res. 2014;115(6):556-566.
[70] Doherty KR, Talbert DR, Trusk PB, et al. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. Toxicol Appl Pharmacol. 2015;285(1):51-60.
[71] Hayakawa T, Kunihiro T, Ando T, et al. Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol. 2014;77:178-191.
[72] Nakamura Y, Matsuo J, Miyamoto N, et al. Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study. J Pharmacol Sci. 2014;124(4):494-501.
[73] Lu J, Wei H, Wu J, et al. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One. 2014;9(12):e115648.
[74] Han L, Li Y, Tchao J, et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.Cardiovasc Res. 2014;104(2): 258-269.
[75] Nozaki Y, Honda Y, Tsujimoto S, et al. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol Appl Pharmacol. 2014;278(1): 72-77.
[76] Rao C, Prodromakis T, Kolker L, et al. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials. 2013;34(10): 2399-2411.
[77] Rodriguez ML, Graham BT, Pabon LM, et al. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J Biomech Eng. 2014;136(5):051005.
[78] Josowitz R, Lu J, Falce C, et al. Identification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expression. PLoS One. 2014;9(7):e101316. |